Every 10-Q that Alpha Teknova, Inc. (TKNO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TKNO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TKNO filings page.
Alpha Teknova, Inc. produces critical reagents for life‑science research, diagnostics, and therapeutics. For the quarter ended June 30, 2026, revenue was $12,185 thousand, up 18.5% year over year, with gross margin improving to 40.1%. Lab Essentials and Clinical Solutions each grew 17.9%.
The company reported a net loss of $3,170 thousand for the quarter and $7,725 thousand for the first half, modestly better than 2025, as operating expenses grew only 3.4% year to date. Operating cash use fell to $3,830 thousand for the first half from $6,204 thousand a year earlier.
Cash and cash equivalents were $6,004 thousand and short‑term U.S. Treasury investments $11,432 thousand, against $13,218 thousand of long‑term debt, all under a credit facility that requires at least $8.0 million of cash and investments. One distributor customer represented 24% of Q2 revenue, and key suppliers each exceeded 20% of purchases. New risk disclosures highlight potential operational, regulatory, and cybersecurity exposures from increased use of artificial intelligence in operations.
Alpha Teknova, Inc. reported Q1 2026 revenue of $11.1 million, up from $9.8 million a year ago, driven by growth in both Lab Essentials and a strong 84.6% increase in Clinical Solutions. Gross margin improved to 34.2% from 30.7%, reflecting better profitability on higher volumes.
The company still posted a net loss of $4.6 million, similar to Q1 2025, though operating loss narrowed slightly. Teknova ended the quarter with $17.8 million in cash, cash equivalents, and short‑term investments, $24.8 million of working capital, and $13.2 million of term debt, and remained in compliance with loan covenants.
Alpha Teknova (TKNO) reported Q3 2025 results. Revenue was $10.5 million, up 9.2% year over year. Gross margin improved to 30.7% from 0.9% a year ago, reflecting the absence of prior-year inventory charges. Operating loss narrowed to $4.0 million, and net loss was $4.3 million (net loss per share of $0.08).
For the first nine months, revenue reached $30.5 million (up 7.2%) with a 33.4% gross margin. General and administrative costs fell year over year, contributing to a smaller operating loss. Cash and cash equivalents plus short‑term investments totaled $22.1 million as of September 30, 2025, within $29.6 million of net working capital.
The company’s amended credit facility totals $28.245 million (term loan and revolver) and includes covenants, including a minimum trailing‑twelve‑month net revenue of $39.0 million for the period ending December 31, 2025, and a minimum cash requirement of $8.0 million. Shares outstanding were 53,529,174 as of November 5, 2025.
Alpha Teknova, Inc. reported revenue of $10.3 million for the quarter ended June 30, 2025, up 7.0% from the prior-year quarter, and $20.1 million for the six months ended June 30, 2025, up 6.2% year-over-year. Gross profit improved materially, with gross margin rising to 38.7% for the quarter (from 29.2%) and to 34.8% for the six months (from 26.5%), driven by stated manufacturing efficiency gains and higher revenue.
The company recorded a net loss of $3.6 million in the quarter and $8.2 million for the six-month period; net loss per share was $0.07 and $0.15, respectively. Balance sheet highlights include total assets of $110.5 million, cash of $3.3 million and short-term held-to-maturity investments of $20.7 million (combined $24.0 million), long-term debt, net of $13.0 million, and stockholders' equity of $76.1 million. The company reports $31.6 million in net working capital.
Liquidity is supported by a $28.245 million credit facility (a $23.245 million term loan and a $5.0 million revolver) that matures in 2030; the facility includes a $39.0 million trailing 12-month minimum net revenue covenant and an $8.0 million minimum cash covenant. Notable concentrations disclosed include Distributor customer A representing 22% of revenue for the quarter and a distributor supplier representing 26% of inventory purchases. The filing shows progress on margin improvement and cost control but the company remains unprofitable with existing debt and concentration risks.